Skip to main content

Table 6 Summary of participants with single or multiple injection-site reactions excluding pain among pooled galcanezumab-treated participants in Study CGAJ and REGAIN (galcanezumab exposure analysis set)

From: Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine

Injection-site reactions, n (%)

Total doses received (N = 1326)

1 to 3

4 to 9

> 10

 1 (26)

2 (7.7)

0

0

 2 (36)

2 (5.6)

0

0

 3 (32)

1 (3.1)

1 (3.1)

0

 4 (35)

6 (17.1)

0

0

 5 (32)

6 (18.8)

0

0

 6 (39)

5 (12.8)

3 (7.7)

0

 7 (29)

7 (24.1)

2 (6.9)

0

 8 (26)

7 (26.9)

0

0

 9a (433)

30 (6.9)

12 (2.8)

2 (0.5)

 10 (9)

3 (33.3)

1 (11.1)

0

 11 (11)

2 (18.2)

0

0

 12 (618)

97 (15.7)

34 (5.5)

6 (1.0)

  1. athe number of patients receiving up to nine doses of galcanezumab, includes patients from both Study CGAJ (Month 0 to Month 12) and REGAIN (galcanezumab, Month 0 to Month 12; and placebo patients who had received placebo treatment from Month 0 to Month 3 and then initiated galcanezumab in the open-label extension phase and could receive up to nine doses of galcanezumab
  2. Abbreviations:N number of galcanezumab-treated participants with a specific number of galcanezumab doses, n number of patients within each specific category
Back to article page